Published in J Pharmacol Exp Ther on June 28, 2012
VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. EMBO Mol Med (2013) 1.22
Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial. Orphanet J Rare Dis (2013) 1.01
Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy. Phys Med Rehabil Clin N Am (2012) 0.98
VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid. Bioorg Med Chem (2013) 0.88
VBP15, a glucocorticoid analogue, is effective at reducing allergic lung inflammation in mice. PLoS One (2013) 0.81
Pharmacologically-induced mitotic synchrony in airway epithelial cells as a mechanism of action of anti-inflammatory drugs. Respir Res (2015) 0.75
Immunogenomics reveal molecular circuits of diclofenac induced liver injury in mice. Oncotarget (2016) 0.75
Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. N Engl J Med (2005) 8.65
DNA binding of the glucocorticoid receptor is not essential for survival. Cell (1998) 6.40
Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J (2001) 2.34
Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures. Muscle Nerve (2009) 2.19
Myogenic cell lines derived from transgenic mice carrying a thermolabile T antigen: a model system for the derivation of tissue-specific and mutation-specific cell lines. Dev Biol (1994) 2.02
Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology (2011) 1.86
Separating transrepression and transactivation: a distressing divorce for the glucocorticoid receptor? Mol Pharmacol (2007) 1.79
Constitutive activation of MAPK cascade in acute quadriplegic myopathy. Ann Neurol (2004) 1.77
The role of the glucocorticoid receptor in inflammation and immunity. J Steroid Biochem Mol Biol (2010) 1.42
Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy. FASEB J (2011) 1.39
Selective Glucocorticoid Receptor modulators. J Steroid Biochem Mol Biol (2010) 1.35
Negative glucocorticoid receptor response elements and their role in glucocorticoid action. Curr Pharm Des (2004) 1.31
Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial. JAMA (1993) 1.28
Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice. J Cardiovasc Pharmacol Ther (2011) 1.28
Diamonds are forever: the cortisone legacy. J Endocrinol (2007) 1.23
Microarray analysis of the temporal response of skeletal muscle to methylprednisolone: comparative analysis of two dosing regimens. Physiol Genomics (2007) 1.10
Autoregulation of glucocorticoid receptor gene expression. Steroids (1991) 1.03
Long-Term Steroid Therapy in Duchenne Muscular Dystrophy-Positive Results versus Side Effects. J Clin Neuromuscul Dis (2001) 1.01
Analysis of the dissociated steroid RU24858 does not exclude a role for inducible genes in the anti-inflammatory actions of glucocorticoids. Mol Pharmacol (2006) 1.00
Non-invasive optical imaging of muscle pathology in mdx mice using cathepsin caged near-infrared imaging. Mol Imaging Biol (2011) 1.00
Relationships between circadian rhythms and modulation of gene expression by glucocorticoids in skeletal muscle. Am J Physiol Regul Integr Comp Physiol (2008) 0.98
A robust in vitro screening assay to identify NF-kappaB inhibitors for inflammatory muscle diseases. Int Immunopharmacol (2009) 0.96
Skeletal muscle dysfunction in critical care: wasting, weakness, and rehabilitation strategies. Crit Care Med (2010) 0.94
Competition between glucocorticoid receptor and NFkappaB for control of the human FasL promoter. FASEB J (2006) 0.92
Duchenne muscular dystrophy: the effect of glucocorticoids on ventilator use and ambulation. Am J Phys Med Rehabil (2010) 0.91
Calcium influx inhibition by steroids and analogs in C2C12 skeletal muscle cells. Br J Pharmacol (1998) 0.90
Gelatinase expression in retinoblastoma: modulation of LH(BETA)T(AG) retinal tumor development by anecortave acetate. Invest Ophthalmol Vis Sci (2010) 0.89
Mathematical modeling of corticosteroid pharmacogenomics in rat muscle following acute and chronic methylprednisolone dosing. Mol Pharm (2008) 0.87
The mechanism of cytoprotective action of lazaroids I: Inhibition of reactive oxygen species formation and lethal cell injury during periods of energy depletion. J Pharmacol Exp Ther (1996) 0.87
Rats with a glucocorticoid-induced catabolic state show symptoms of oxidative stress and spleen atrophy: the effects of age and recovery. J Vet Med A Physiol Pathol Clin Med (2002) 0.86
Lazaroids: efficacy and mechanism of action of the 21-aminosteroids in neuroprotection. Br J Anaesth (2001) 0.86
Mechanism of action of the angiostatic cortisene anecortave acetate. Surv Ophthalmol (2007) 0.84
Antioxidant activity of U-83836E, a second generation lazaroid, during myocardial ischemia/reperfusion injury. Free Radic Res (1997) 0.82
The lazaroid, U-74389G, inhibits inducible nitric oxide synthase activity, reverses vascular failure and protects against endotoxin shock. Eur J Pharmacol (1999) 0.81
Inhibition of tumour necrosis factor and reversal of endotoxin-induced shock by U-83836E, a 'second generation' lazaroid in rats. Br J Pharmacol (1998) 0.79
Effect of lazaroid U-74389G and methylprednisolone on endotoxin-induced shock in mice. Surgery (1999) 0.78
Steroid therapy is associated with decreased numbers of dendritic cells and fibroblasts, and increased numbers of satellite cells, in the dystrophic skeletal muscle. J Clin Pathol (2010) 0.78
Forced MyHCIIB expression following targeted genetic manipulation of conditionally immortalized muscle precursor cells. Exp Cell Res (1999) 0.77
Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med (2009) 5.54
Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt. Dev Cell (2008) 5.51
Genomics, intellectual disability, and autism. N Engl J Med (2012) 3.74
Elevated stearoyl-CoA desaturase-1 expression in skeletal muscle contributes to abnormal fatty acid partitioning in obese humans. Cell Metab (2005) 3.47
Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med (2005) 2.82
An interactive power analysis tool for microarray hypothesis testing and generation. Bioinformatics (2006) 2.62
The University of Tennessee's accelerated family medicine residency program 1992-2002: an 11-year report. Fam Med (2005) 2.35
Sources of variability and effect of experimental approach on expression profiling data interpretation. BMC Bioinformatics (2002) 2.31
Maintaining confidentiality of interim data to enhance trial integrity and credibility. Clin Trials (2008) 2.26
Nuclear envelope dystrophies show a transcriptional fingerprint suggesting disruption of Rb-MyoD pathways in muscle regeneration. Brain (2006) 2.22
Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy. Neurobiol Dis (2008) 2.20
Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures. Muscle Nerve (2009) 2.19
Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arterioscler Thromb Vasc Biol (2005) 2.12
Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. J Clin Invest (2009) 2.10
Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc Natl Acad Sci U S A (2008) 2.06
Gene profiling in spinal cord injury shows role of cell cycle in neuronal death. Ann Neurol (2003) 2.06
SLC30A8 nonsynonymous variant is associated with recovery following exercise and skeletal muscle size and strength. Diabetes (2013) 2.05
Calorie-related rapid onset of alveolar loss, regeneration, and changes in mouse lung gene expression. Am J Physiol Lung Cell Mol Physiol (2003) 2.04
Secreted proteome profiling in human RPE cell cultures derived from donors with age related macular degeneration and age matched healthy donors. J Proteome Res (2006) 2.04
Deacetylase inhibitors increase muscle cell size by promoting myoblast recruitment and fusion through induction of follistatin. Dev Cell (2004) 2.01
Interactively optimizing signal-to-noise ratios in expression profiling: project-specific algorithm selection and detection p-value weighting in Affymetrix microarrays. Bioinformatics (2004) 1.98
Variability in muscle size and strength gain after unilateral resistance training. Med Sci Sports Exerc (2005) 1.95
ACE ID genotype and the muscle strength and size response to unilateral resistance training. Med Sci Sports Exerc (2006) 1.86
Loss of emerin at the nuclear envelope disrupts the Rb1/E2F and MyoD pathways during muscle regeneration. Hum Mol Genet (2006) 1.85
Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol (2002) 1.83
Tissue-specific alternative splicing of TCF7L2. Hum Mol Genet (2009) 1.80
Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med (2002) 1.78
The RNA helicases p68/p72 and the noncoding RNA SRA are coregulators of MyoD and skeletal muscle differentiation. Dev Cell (2006) 1.78
Constitutive activation of MAPK cascade in acute quadriplegic myopathy. Ann Neurol (2004) 1.77
Regulation of mucin genes in chronic inflammatory airway diseases. Am J Respir Cell Mol Biol (2006) 1.74
GRB14, GPD1, and GDF8 as potential network collaborators in weight loss-induced improvements in insulin action in human skeletal muscle. Physiol Genomics (2006) 1.67
Dysferlin deficiency enhances monocyte phagocytosis: a model for the inflammatory onset of limb-girdle muscular dystrophy 2B. Am J Pathol (2008) 1.65
Deconstructing Pompe disease by analyzing single muscle fibers: to see a world in a grain of sand... Autophagy (2007) 1.60
Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers. Mol Ther (2005) 1.59
ACTN3 genotype is associated with increases in muscle strength in response to resistance training in women. J Appl Physiol (1985) (2005) 1.57
Embryonic myogenesis pathways in muscle regeneration. Dev Dyn (2004) 1.57
Differential dependency network analysis to identify condition-specific topological changes in biological networks. Bioinformatics (2008) 1.56
Novel approach to inhibit asthma-mediated lung inflammation using anti-CD147 intervention. J Immunol (2006) 1.56
Microtubules underlie dysfunction in duchenne muscular dystrophy. Sci Signal (2012) 1.54
Probe set algorithms: is there a rational best bet? BMC Bioinformatics (2006) 1.53
Dystrophin-deficient cardiomyopathy in mouse: expression of Nox4 and Lox are associated with fibrosis and altered functional parameters in the heart. Neuromuscul Disord (2008) 1.52
ACTN3 and MLCK genotype associations with exertional muscle damage. J Appl Physiol (1985) (2005) 1.52
Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies. J Clin Invest (2015) 1.51
Functional characteristics of dystrophic skeletal muscle: insights from animal models. J Appl Physiol (1985) (2002) 1.50
Slug is a novel downstream target of MyoD. Temporal profiling in muscle regeneration. J Biol Chem (2002) 1.50
Functional polymorphisms associated with human muscle size and strength. Med Sci Sports Exerc (2004) 1.49
The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used. Muscle Nerve (2013) 1.48
Proteomics and systems biology in exercise and sport sciences research. Exerc Sport Sci Rev (2007) 1.43
Inflammasome up-regulation and activation in dysferlin-deficient skeletal muscle. Am J Pathol (2010) 1.41
Patterns of global gene expression in rat skeletal muscle during unloading and low-intensity ambulatory activity. Physiol Genomics (2003) 1.41
The PEPR GeneChip data warehouse, and implementation of a dynamic time series query tool (SGQT) with graphical interface. Nucleic Acids Res (2004) 1.40
Rare missense and synonymous variants in UBE1 are associated with X-linked infantile spinal muscular atrophy. Am J Hum Genet (2008) 1.39
Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder--murine Pompe disease. Autophagy (2010) 1.38
A web-accessible complete transcriptome of normal human and DMD muscle. Neuromuscul Disord (2002) 1.38
Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. Proc Natl Acad Sci U S A (2012) 1.32
Skipping toward personalized molecular medicine. N Engl J Med (2007) 1.30
Response of rat muscle to acute resistance exercise defined by transcriptional and translational profiling. J Physiol (2002) 1.29
Integrated DNA, cDNA, and protein studies in Becker muscular dystrophy show high exception to the reading frame rule. Hum Mutat (2008) 1.29
Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies. Mamm Genome (2012) 1.28
Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice. J Cardiovasc Pharmacol Ther (2011) 1.28
Fgfr4 is required for effective muscle regeneration in vivo. Delineation of a MyoD-Tead2-Fgfr4 transcriptional pathway. J Biol Chem (2005) 1.27
One-year treatment of morpholino antisense oligomer improves skeletal and cardiac muscle functions in dystrophic mdx mice. Mol Ther (2010) 1.25
VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. EMBO Mol Med (2013) 1.22
Novel CLCN1 mutations with unique clinical and electrophysiological consequences. Brain (2002) 1.22
Balancing muscle hypertrophy and atrophy. Nat Med (2004) 1.22
A randomized clinical trial to assess the effect of statins on skeletal muscle function and performance: rationale and study design. Prev Cardiol (2010) 1.21
In vivo and in vitro characterization of novel neuronal plasticity factors identified following spinal cord injury. J Biol Chem (2004) 1.20
Glycogen stored in skeletal but not in cardiac muscle in acid alpha-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme. Mol Ther (2002) 1.19
Olfactory biopsies demonstrate a defect in neuronal development in Rett's syndrome. Ann Neurol (2003) 1.19
Gene expression profiling of experimental traumatic spinal cord injury as a function of distance from impact site and injury severity. Physiol Genomics (2005) 1.19
An analysis of DNA methylation in human adipose tissue reveals differential modification of obesity genes before and after gastric bypass and weight loss. Genome Biol (2015) 1.19
Proteome analysis of skeletal muscle from obese and morbidly obese women. Diabetes (2005) 1.18
In vivo filtering of in vitro expression data reveals MyoD targets. C R Biol (2004) 1.18
Expression profiling reveals metabolic and structural components of extraocular muscles. Physiol Genomics (2002) 1.17
Molecular responses of human muscle to eccentric exercise. J Appl Physiol (1985) (2003) 1.17
Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy. Neurology (2012) 1.17
Direct analysis of lipids and small metabolites in mouse brain tissue by AP IR-MALDI and reactive LAESI mass spectrometry. Analyst (2010) 1.17
Skeletal muscle dictates the fibrinolytic state after exercise training in overweight men with characteristics of metabolic syndrome. J Physiol (2003) 1.15
Expression of two temporally distinct microglia-related gene clusters after spinal cord injury. Glia (2006) 1.14
Sedation using dexmedetomidine in pediatric burn patients. J Burn Care Res (2006) 1.13
Dysferlin deficiency shows compensatory induction of Rab27A/Slp2a that may contribute to inflammatory onset. Am J Pathol (2008) 1.12